Coronavirus (Covid -19) and Type 2 Diabetes

New safety guidance from the Medicines and Healthcare products Regulatory Agency (MHRA) suggests SGLT2 inhibitor treatment which includes Invokana, should be interrupted in patients who are hospitalised for major surgical procedures or acute serious medical illnesses and ketone levels measured, preferably in blood rather than urine. Treatment may be restarted when the ketone values are normal and the patient’s condition has stabilised.

It is important that people with diabetes follow the sick day rules should they become ill from any illness.

This website is intended for UK healthcare professionals only
Prescribing information can be found here
A recommended EASD consensus report 2019 SGLT2i logo
Invokana (canagliflozin) is a member of the newest class of diabetes medicines (SGLT2 inhibitors)

Protect the kidneys
Protect the heart

Invokana is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus (T2DM) as an adjunct to diet and exercise. For treatment of diabetic kidney disease (DKD) in adults with T2DM as add-on to standard of care, a dose of 100 mg once-daily should be used. See SmPC section 4.2 for dosing details.

Request more information
A recommended EASD consensus report 2019 SGLT2i logo

The 1st and only SGLT2i also licensed to treat diabetic kidney disease (DKD) in T2DM1-4

Now for treatment of people with severe albuminuria from early identification until dialysis or renal transplantation

Watch video to find out more about the CREDENCE trial
Invokana (canagliflozin) Logo - Protect the heart Protect the kidney
Invokana logo

Protect the kidneys
Protect the heart

Invokana is indicated for the treatment of adults with insufficiently
controlled type 2 diabetes mellitus (T2DM) as an adjunct to diet and exercise.
For treatment of diabetic kidney disease (DKD) in adults with T2DM as
add-on to standard of care, a dose of 100 mg once-daily should be used.
See SmPC section 4.2 for dosing details.

Request more information
A recommended EASD consensus report 2019 SGLT2i logo

The 1st and only SGLT2i also licensed to treat
diabetic kidney disease (DKD) in T2DM1-4

Now for treatment of people with severe albuminuria from
early identification until dialysis or renal transplantation

Watch video to find out more about the CREDENCE trial
References
  1. Reference 21
  2. Reference 22
  3. Reference 23
  4. Reference 24

Date of preparation: October 2020 | Job code:UK-INV-2000072